Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study
University Hospital, Strasbourg, France
50 participants
Apr 20, 2025
OBSERVATIONAL
Conditions
Summary
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
Eligibility
Inclusion Criteria3
- Patients over 18 years of age
- Metastatic urothelial carcinoma
- Treated with first-line metastatic therapy since October 2024
Exclusion Criteria1
- Patient who expressed opposition to participating in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07339878